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Abstract
Expression profiling of clinically obtainable tumor
specimenshasbeenhinderedby theneed formicrogram
quantities of RNA. In vitro transcription (IVT)–based am-
plifications are most commonly used to amplify small
quantities of RNA for microarray analysis. However, sig-
nificant drawbacks exist with IVT-based amplification,
and the need for alternative amplification methods
remains. Herein, we validate whole transcriptome am-
plification (WTA), an exponential amplification tech-
nique that produces cDNA libraries and amplified
target in 3 to 4 hours from nanogram quantities of total
RNA using a combination of cDNA microarrays and
quantitative polymerase chain reaction (PCR). We dem-
onstrate that WTA material can serve as a ‘‘molecular
archive’’ because a WTA cDNA library can be faithfully
amplified through multiple rounds of PCR amplification,
allowing it to serve as a bankable and distributable
resource. To demonstrate applicability, WTA was com-
bined with laser capture microdissection to profile
frozen prostate tissues. Unlike most IVT-based and ex-
ponential amplification techniques, WTA does not
depend on the presence of a poly-A tail. Thus, we dem-
onstrate that WTA is compatible with artificially de-
graded RNA and RNA isolated from formalin-fixed
paraffin-embedded tissues. Taken together, WTA repre-
sents a versatile approach to profile and archive cDNA
from minute tumor samples and is compatible with par-
tially degraded RNA.
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Introduction
Profiling human cancer samples has become a standard
technique in cancer research. With a few exceptions [1–6],
most cancer profiling studies have used bulk tumors due to
the requirement for at least 5 mg of total RNA. Interest in
profiling clinically obtainable specimens, by needle biopsy, fine
needle aspiration, or laser capture microdissection (LCM),
has led to the development of techniques to amplify RNA.
Currently, the most widely used and validated technique is T7
polymerase–based in vitro transcription (IVT) [7,8]. The cost,
speed, labor, and requirement for multiple rounds of amplifi-
cation from limiting samples have prompted the investigation
of various polymerase chain reaction (PCR)–based ampli-
fication techniques and their applicability to microarray profiling
[9–14]. However, these methods also have significant draw-
backs, including the requirement of a poly-A tail [10,12–14],
the requirement to produce double-stranded cDNA before
amplification [11], extreme 3V bias requiring custommicroarrays
[10], or that they are a combination of PCR and IVT-based
techniques [13].
In this report, we describe the evaluation of OmniPlex whole
transcriptome amplification (WTA) with respect to the amplifi-
cation of RNA from specimens of interest to the cancer re-
searcher. WTA is a simple amplification protocol that is
analogous to OmniPlex whole genome amplification (WGA)—
a rapid, robust, and unbiased method used to amplify genomic
DNA using genome fragmentation followed by linker attach-
ment and PCR amplification [15]. In WTA, RNA undergoes a
single-step conversion into cDNA fragments flanked by univer-
sal priming sites, with subsequent PCR amplification of the
resulting cDNA library using universal oligonucleotide primers.
Importantly, WTA does not depend on the presence of a poly-A
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tail, resulting in a uniform amplification of template RNA
without bias to the 3V end.
Herein, we evaluate the reproducibility of WTA and its use
for identifying differentially expressed genes using cDNA
microarrays and quantitative real-time PCR (QPCR) from
tissue samples and cell lines. We also demonstrate that
WTA- amplified samples can serve as a reusable library or
‘‘molecular archive’’ because multiple rounds of WTA PCR
amplification from a WTA cDNA library are reproducible and
can produce enough target for thousands of microarrays.
We also combine LCM with WTA to identify genes that are
differentially expressed between benign epithelial cells,
cancerous epithelial cells, and stroma isolated from frozen
prostate tissue sections. As WTA does not depend on a poly-
A tail to prime the reaction, we demonstrate that WTA can
be used to profile partially degraded RNA, as well as benign
and cancerous prostate sections from formalin-fixed paraffin-
embedded (FFPE) tissues. Taken together, these results
validate the applicability ofWTA for studying gene expression
from a variety of tumor specimens.
Materials and Methods
Samples
All prostate tissue specimens were obtained with written
patient consent and approval of the University of Michigan
Institutional Review Board. These tissues were stored in the
University of Michigan Prostate SPORE Tissue Bank. For
WTA reproducibility studies, we used a commercially avail-
able pool of benign prostate tissue total RNA (CPP; Clon-
tech, Mountain View, CA). For WTA evaluation studies, both
tissue samples and cell line samples were used for RNA
isolation. One prostate cancer tissue specimen (PCA1) was
used with the same lot of CPP as the reference for the set
of experiments. Total RNA was also isolated from the pros-
tate cancer cell line LnCAP, with cells treated with 1 nM of
the synthetic androgen R1881 (LnCAP_R) or ethanol as
control (LnCAP_C) for 24 hours before RNA isolation. Tissue
and cell line samples were homogenized in Trizol (Invitrogen,
Carlsbad, CA), and total RNA was isolated using the stan-
dard Trizol protocol. Denaturing formaldehyde agarose gel
electrophoresis or Bioanalyzer 2100 (Agilent, Palo Alto, CA)
was used to verify total RNA integrity. RNA was quantified
using ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE) and/or Ribogreen (Molecular Probes,
Eugene, OR).
WTA Amplification
The OmniPlex WTA described in this report was per-
formed using a TransPlex WTA kit (Rubicon Genomics,
Inc., Ann Arbor, MI). The indicated amounts of total RNA in
a volume of 25 ml were converted into OmniPlex WTA cDNA
libraries and amplified by WTA PCR using reagents and
protocols supplied with or recommended by beta-commercial
TransPlex WTA kits (www.rubicongenomics.com). Briefly,
RNAse-free water was added with the indicated amount of
total RNA to a volume of 16.5 ml. A 5 library synthesis buffer
(1 final concentration) and a 10 library stabilization buffer
were added; the mixture was heated at 70jC for 5 minutes
and immediately cooled. One microliter of library synthesis
enzyme was added, and WTA cDNA libraries were synthe-
sized using the following thermocycler program: 24jC for
15 minutes, 42jC for 2 hours, and 95jC for 5 minutes.
Aliquots were WTA PCR-amplified using Titanium Taq poly-
merase (Clontech) in the presence of amino-allyl deoxy-
uridine triphosphate (dUTP) for postamplification labeling.
For hybridizations using reamplified WTA products, multiple
1- to 5-ng aliquots of the initial WTA PCR reaction were
subjected to an additional WTA PCR amplification in the
presence of amino-allyl dUTP, and products were pooled
before hybridization. Yields after all WTA PCR amplifications
were between 2 and 5 mg per reaction, and reaction progress
was monitored in real time using SYBR Green I (Molecular
Probes) on iCycler IQ (BioRad, Hercules, CA) or ABI 7300
Real-Time PCR System (Applied Biosystems, Foster City,
CA). Real-time PCR amplifications were terminated at or
before plateau phase, as measured by fluorescence incor-
poration, to preserve maximum representation. A range of 10
to 30 mg of Cy3- and Cy5-labeled product was evaluated for
hybridization, as described in Table W1.
cDNA Microarray Procedures
The 20K-element spotted cDNA microarrays used were
constructed essentially as described [16–18]. The complete
list of sequence-verified clones is presented in Table W2,
and all clones are available from Research Genetics (Hunts-
ville, AL) (www.resgen.com).
The complete details of the printing, postprocessing, la-
beling, and hybridization of the arrays are available in the
MIAME checklist (supplementary materials). For microarray
experiments using unamplified total RNA, 30 mg of total RNA
from PCA1, CPP, LnCAP_C, and LnCAP_R was used for
target synthesis in the presence of oligo-dTand random prim-
ers. For WTA samples, after incorporation of dUTP in the
final WTA PCR reaction and purification, amplified target
was labeled and hybridized as for the unamplified samples.
Data Analysis
Arrays were scanned with an Axon 4000B scanner, and
primary analysis was performed using Genepix 4.0 software
package (Axon Instruments, Sunnyvale, CA). For all arrays
described in this study, features flagged by GenePix as not
found during grid alignment and areas of obvious defects were
excluded from further analysis. For reproducibility studies
using self–self hybridizations, features were ranked based
on the sum of the medians (Cy3 + Cy5 intensity), and the top
50% was used. All included features were normalized to set
the aggregatemedian of ratios (Cy5/Cy3) to one. Background-
corrected mean Cy3 and Cy5 intensities for all included
features (Table W3) were plotted using Microsoft Excel.
For all other arrays, features on each array were filtered
based on the rank of the sum of the medians (tissue sam-
ples and cell line samples, top 50% used; LCM and FFPE
samples, top 25% used), and the median of ratios (log2 of
Cy5/Cy3) was normalized using locally weighted regression
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(LOWESS) with a window of 0.6 using custom software
written in Perl and R. Finally, to remove unreliable data, fea-
tures showing an average normalizedmedian of ratios of >1.5
or <0.75 across a series of 11 self–self hybridizations (in-
cluding dye swaps and spanning print runs used in this study)
were removed from all arrays. Cy5/Cy3 (normalized log2)
ratios for these hybridizations can be found in Table W2.
To create the composite array for the tissue samples from
the five unamplified hybridizations, features were flagged
as described above and only features present on at least
four of five arrays were included. The normalized median of
ratios for each featurewas thenaveraged to create the compo-
site array. The intensity-dependent Z score analysis used for
the cell line hybridizations was performed essentially as de-
scribed [19], using a sliding window of 50 features to calculate
the local mean, standard deviation, and Z score for each
feature on the array using custom software written in Perl.
For all analyses, features were clustered usingCluster or were
visualized directly with TreeView, as indicated in the text [20].
QPCR
WeperformedQPCRusingSYBRGreen, aspreviously de-
scribed [21,22]. Briefly,WTA and (directly) reverse-transcribed
cDNA, as indicated, were analyzed. The amount of each
target gene relative to the housekeeping gene glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) for each
sample was determined using the comparative threshold
cycle (Ct) method (Applied Biosystems user bulletin 2;
http://docs.appliedbiosystems.com/pebiodocs/04303859.
pdf), with the unamplified CPP cDNA sample for each gene
serving as calibrator. All primers were synthesized by Inte-
grated DNA Technologies, and sequences are available on
request. AMACR [21], EZH2 [22], TPD52 [23], HMBS, and
GAPDH [24] primers were as described. Approximately
equal efficiencies of the primers were confirmed previously
using serial dilutions of prostate cDNA to use the compara-
tive Ct method.
LCM
LCM was used to isolate approximately 5000 to 10,000
cells from frozen prostate tissue specimens from separate
patients. One to three serial sections were used per sample.
Epithelia from cancerous glands were isolated from four
samples (LCM_PCA1–4), epithelia from benign glands were
isolated from five samples (LCM_NOR1–5), and stroma
adjacent to cancerous glands (LCM_STROMA1) or stroma
from a nodule of benign prostatic hyperplasia (LCM_
STROMA2) were captured. To prepare slides for LCM, a
6-mm slice was cut with a cryostat from the prostate cancer
tissue block embedded in OCT (Sakura, Tokyo, Japan) and
placed on a specially manufactured membrane slide (MMI,
Knoxville, TN). The slide was placed in distilled water and
stained with Harris hematoxylin for 50 seconds, followed
by two short water washes in distilled water. Eosin staining
was performed for 30 seconds. Excessive eosin was rinsed
off with distilled water, and slides were air-dried. Fixation or
dehydration with ethanol was avoided. The SL Microtest
device (MMI) using the mCUT software was used for LCM.
Areas of interest were circled and cut by UV laser. Isolated
cells were picked up using the adhesive surface of the lid of
specially manufactured tubes (MMI). Total RNA was isolated
from each sample using the RNAqueous Micro Kit, treated
with DNase I (Ambion Diagnostics, Austin, TX) according to
the manufacturer’s instructions, quantified with Ribogreen
(Molecular Probes), subjected to WTA cDNA synthesis and
two rounds of WTA PCR amplification in parallel with an
equal amount of CPP, and hybridized (LCM sample versus
CPP) as described above.
RNA Hydrolysis
Artificial degradation of total RNA was performed essen-
tially as described [25]. Total RNA (2.5 mg in 2.5 ml) isolated
from LnCAP_C and LnCAP_R cells, as described above,
was added to 2.5 ml of 5 first-strand cDNA synthesis buffer
(Invitrogen). RNA was then heated to 80jC for 5 or 15 min-
utes. After heating, 500 ng of each sample was analyzed
on an RNA Nano LabChip using Bioanalyzer 2100 (Agilent),
and RNA was quantified with an ND-1000 spectrophoto-
meter. Twenty-five nanograms of each artificially degraded
sample was used for WTA cDNA synthesis and two rounds of
WTA PCR amplification, and hybridized (LnCAP_R versus
LnCAP_C for each time point) as described above.
FFPE Tissue RNA Isolation
Total RNAwas extracted from FFPE tissue samples using
an Optimum FFPE RNA Isolation Kit (Ambion Diagnostics)
according to the manufacturer’s instructions. Total RNA was
isolated from three cases, with two containing clinically
localized prostate adenocarcinoma (FFPE_PCA1–2) and
one containing only benign prostate tissue (FFPE_NOR1).
FFPE_PCA1 and FFPE_PCA2 were embedded in 2003, and
FFPE_NOR1was embedded in 1995. Briefly, two 10-mmsec-
tions were cut from the paraffin block, immediately placed in
a microcentrifuge tube, and stored at 80jC until RNA isola-
tion. Sections were twice incubated in xylene for 10 minutes,
followed by an ethanol gradient wash. After overnight incu-
bation with proteinase K, RNA was isolated, treated with
DNase I, and quantified using an ND spectrophotometer.
RNA integrity was determined using denaturing formalde-
hyde agarose gel electrophoresis. Twenty-five nanograms of
each sample was used for WTA cDNA synthesis and two
rounds of WTA PCR amplification, and hybridized (FFPE_
PCA1–2 or FFPE_NOR1 vs CPP) as described above.
Results
Reproducibility of WTA for Gene Expression Profiling
and Construction of Molecular Archives
In this report, we describe the evaluation of WTA, a
novel non–T7-based exponential RNA amplification method
(Figure 1A). Initially, the transcriptome is converted to a
cDNA library of controlled fragment length with identical
linkers on the 5V and 3V ends. To synthesize the library, sam-
ple RNA is incubated with a reverse transcriptase in the
presence of non–self-complementary primers comprised of
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a quasi-random 3V end and a universal 5V end. When an-
nealed primers are extended by a polymerase, displaced
single strands are generated, which become new templates
for primer annealing and extension. This process creates a
cDNA library comprised of random, overlapping 100- to
1000-base fragments flanked by a universal end sequence.
Universal primer PCR is then used to amplify the cDNA li-
brary and to produce WTA products.
To validate WTA for expression profiling, we began by
evaluating the reproducibility of WTA using a series of self–
self hybridizations on 20K-element cDNA microarrays. Two
identical 25-ng aliquots of total RNA from a commercially
available pool of benign prostate tissue (CPP) were con-
verted into WTA cDNA libraries and subjected to one round
of WTA PCR amplification. Fifteen micrograms of amplified
cDNA from each aliquot was labeled with Cy3 or Cy5, and
hybridized competitively on the same array. This experiment
was also repeated with separate RNA aliquots subjected to
WTA cDNA synthesis and two, three, or four rounds of WTA
PCR amplification before labeling and hybridization. Back-
ground-corrected mean Cy5 vs Cy3 intensities were plotted
and displayed as scatter plots (Figure 1B). Pearson correla-
tion coefficients (R2; one-round WTA PCR = 0.9910; two-
round WTA PCR = 0.9856; three-round WTA PCR = 0.9726;
four-round WTA PCR = 0.9612) reveal excellent reproduc-
ibility for WTA cDNA library synthesis and one, two, three, or
four rounds of WTA PCR amplification. When amplified
products produced from different rounds of WTA product
were competitively hybridized (Cy3, four rounds; Cy5, two
rounds), they showed reduced correlation (R2 = 0.8361),
demonstrating that samples, to be hybridized, should be
subjected to the same number of WTA PCR rounds.
As each WTA PCR amplification produces microgram
quantities of cDNA products and only nanograms are re-
quired for subsequent PCR amplifications, WTA cDNA prod-
ucts can serve as ‘‘molecular archives,’’ which can be
faithfully reamplified. To demonstrate the stability of these
‘‘molecular archives,’’ a separate 25-ng aliquot of CPP total
RNA was converted into a WTA cDNA library and subjected
to one round of WTA PCR amplification. One aliquot of this
WTA-amplified cDNA was subjected to a second round of
WTA PCR amplification immediately, whereas another ali-
quot was taken 6 months later and subjected to a second
round of WTA PCR. The products were labeled with Cy3 or
Cy5, and hybridized together as above, with R2 = 0.9923.
Fidelity of WTA for Detecting Differentially
Expressed Genes
As one of the main uses for microarrays is the detection
of genes differentially expressed between benign and
Figure 1. Non–T7-polymerase based WTA strategy and reproducibility. (A) Initially, the RNA transcriptome (red) is converted to a WTA cDNA library using a
reverse transcriptase in the presence of non–self-complementary primers consisting of a quasi-random 3 V end (black arrow) and a universal 5 V end (blue).
Extension of annealed primers by a polymerase generates single strands, which become new templates for primer annealing and extension. This process creates a
cDNA library of random, overlapping 100- to 1000-base fragments with universal end sequences. These fragments are then amplified by one or more rounds of
WTA PCR using primers specific for the universal ends. Amino-allyl dUTP is incorporated in the WTA PCR amplification for subsequent labeling, and WTA PCR
amplification can be monitored in real time using SYBR Green to ensure maximum representation and to avoid saturation. The entire library creation and one round
of WTA PCR amplification take 3 to 4 hours using the manufacturer’s protocol. (B) Scatter plots of self – self hybridizations demonstrate the reproducibility of WTA.
Two identical 25-ng aliquots of a benign prostate tissue pool (CPP) were converted into WTA cDNA libraries and subjected to one, two, three, or four rounds of
WTA PCR amplification, as indicated before labeling with Cy3 or Cy5 and hybridization together on 20K-element spotted cDNA microarrays. Background-corrected
mean Cy3 intensity vs. background-corrected mean Cy5 intensity was plotted, and Pearson correlation coefficients (R2) are indicated.
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cancerous tissues, we sought to validate WTA for this
application. We began by profiling tissue samples represent-
ing benign and cancerous prostate tissues, which we ex-
pected to have a large number of differentially expressed
genes based on our previous profiling studies [16,17]. Total
RNA from the same clinically localized prostate cancer
specimen (PCA1) and CPP was used directly or WTA-
amplified before hybridization. Five replicate hybridizations
from unamplified total RNA were performed with PCA1 la-
beled with Cy5, and with CPP labeled with Cy3, to create a
composite unamplified array, as described in the Materials
and Methods section. We then performed seven hybridiza-
tions after WTA cDNA library synthesis and a single round
of WTA PCR amplification on a range of input total RNA
(300 ng–12.5 ng) from the same samples, PCA1 (labeled
with Cy5) and CPP (labeled with Cy3). After filtering, as de-
scribed in the Materials and Methods section, features from
each WTA hybridization were compared to the composite
array. We identified 345 of 7564 features on the composite
unamplified array that showed a >3-fold differential ex-
pression, and their expression ratios were visualized along
with their corresponding values from WTA hybridizations
(Figure 2A). The correlation coefficient (R) between the
expression ratios of all 7564 features on the composite
unamplified array and the average expression ratio of the
seven WTA hybridizations is 0.84. The correlation coefficient
for the 345 features on the composite array showing a
>3-fold differential expression is 0.99. From these initial
experiments, we determined that hybridization of 10 mg of
amplified products (both control and experimental) is suffi-
cient starting with >100 ng of input RNA, whereas 15 to 20 mg
is optimal for hybridizations starting with less RNA.
To further evaluate WTA technology, QPCR was used to
determine the expression of 23 genes. These genes were
selected to represent both unchanged and differentially ex-
pressed genes that spanned the intensity spectrum of the
composite unamplified array to assess the fidelity of WTA
for both high- and low-copy-number transcripts. Relative
quantities of these genes, compared to the housekeeping
gene GAPDH, were determined in unamplified reverse-
transcribed cDNA and WTA cDNA (Figure 2B). Twenty five
nanograms of input total RNA was used for WTA cDNA syn-
thesis and one round of WTA PCR amplification.
We then sought to determine the fidelity of WTA for
samples with limited numbers of differentially expressed
genes. We used total RNA from the prostate cancer cell
line LnCAP treated with the synthetic androgen R1881
(LnCAP_R) or control (LnCAP_C). Unamplified total RNA
was used to produce hybridization with LnCAP_R labeled
with Cy5, and with LnCAP_C labeled with Cy3. Six hybridi-
zations were then performed after WTA cDNA library synthe-
sis and one or two rounds of WTA PCR amplification on
a range of input total RNA (25 ng–100 pg) from the same
samples, LnCAP_R (labeled with Cy5) and LnCAP_C
Figure 2. Concordance of differentially expressed genes between unamplified and WTA-amplified total RNA. (A) Unamplified total RNA from a prostate cancer
tissue specimen (PCA1, Cy5) was hybridized against unamplified total RNA from benign prostate tissues (CPP, Cy3), and five replicate hybridizations were
averaged to create a composite array. The indicated amounts of the same total RNA were then converted into WTA cDNA libraries, amplified by one round of WTA
PCR and hybridized for comparison. The 345 features identified as being differentially expressed by >3-fold on the composite array (Unamplified) and their
corresponding expression values from the indicated WTA hybridizations and the average of the seven WTA arrays (WTA_AVG) were visualized using TreeView.
Columns represent individual hybridizations using the indicated amount of input total RNA for WTA (as described in Table W1), and rows represent individual
features. Red and green cells represent upregulation or downregulation, respectively (see scale at the bottom), in PCA1 compared to CPP. Black cells indicate
probes with roughly equivalent expression, and grey cells indicate features not passing filtering. (B) Validation of WTA fidelity using QPCR. Directly reverse-
transcribed cDNA (UNAMP) or WTA cDNA (WTA; from 25 ng of input total RNA, WTA cDNA library synthesis, and one round of WTA PCR amplification) from the
same samples used for microarray analysis in (A) PCA1 and CPP was assessed using QPCR. The amount of each target gene in PCA1 and CPP was normalized
to the amount of GAPDH for the sample. Data are presented as the ratio of PCA1 to CPP for each target gene on a log scale. (C) Unamplified total RNA from the
prostate cancer cell line LnCAP treated with the synthetic androgen R1881 (LnCAP_R, Cy5) was hybridized against unamplified total RNA from LnCAP cells
treated with vehicle (LnCAP_C). The indicated amounts of the same total RNA were used for WTA cDNA library synthesis followed by one (1j) or two (2j) rounds
of WTA PCR amplification and hybridized for comparison. The top 29 differentially expressed features from the unamplified array (z4 Z score units, minimum of
1.97-fold upregulated, or 1.78-fold downregulated LnCAP_R/LnCAP_C) and their corresponding expression values from the WTA hybridizations were visualized
using TreeView as above. The number below each column indicates the percentage of these top 29 differentially expressed features identified in the unamplified
array that had Z scores z1 or z2 on the indicated WTA hybridization. The complete gene lists from all heat maps are available in Table W4.
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(labeled with Cy3). As expected, a much smaller set of fea-
tures was differentially expressed (eight features z3-fold
differential expression) compared to the tissue sample
experiments described above. Thus, we used intensity-
dependentZ scores, amore sensitivemeasure than standard
fold change [19], to identify the top 29 differentially expressed
features (z4 Z score units, a minimum of 1.97-fold upregu-
lated or 1.78-fold downregulated LnCAP_R/LnCAP_C) on
the unamplified array. The expression values for these
29 features from the unamplified array and the correspond-
ing values from the WTA hybridizations were visualized
(Figure 2C). To quantify the ability of WTA to maintain dif-
ferential expression, we determined the percentage of these
top 29 differentially expressed features identified in the
unamplified array that had Z scores z1 or z2 (in the same
direction) on each WTA hybridization, as shown below each
column in Figure 2C. These experiments demonstrate that
WTA maintains expression patterns of differentially ex-
pressed genes with as little as 100 pg to 1 ng of input total
RNA, although hybridizations from <10 ng of input total RNA
haddecreasedcorrelation to theunamplified composite array.
Hybridizations after WTA cDNA synthesis and two rounds
of WTA PCR also improved the correlation with unamplified
total RNA. Taken together, these experiments demonstrate
that WTA faithfully maintains differential expression over a
wide range of input RNA and is applicable to profiling can-
cerous tissue or cell line samples.
LCM and WTA for Profiling Benign Prostate Epithelium,
Cancerous Epithelium, and Stroma
After validating WTA with minimal amounts of cell line and
tissue samples, we investigated the ability of WTA to detect
differentially expressed genes from material obtained by
LCM. Total RNA was isolated from 5000 to 10,000 cells
obtained by LCM from 11 samples. Separate cases were
used for each sample, with five samples of epithelium from
benign glands (LCM_NOR1–5) and four samples of cancer-
ous epithelium (LCM_PCA1–4). Two stromal samples were
also captured: one isolated from stroma adjacent to can-
cerous glands (LCM_STROMA1) and a second sample from
a nodule of benign prostatic hyperplasia (BPH) (LCM_
STROMA2). Ten to 45 ng of total RNA was isolated per sam-
ple. WTA cDNA library synthesis and two rounds of WTA PCR
amplification were used to produce labeled targets for hy-
bridization from 10 ng of isolated total RNA. Fifteen micro-
grams of the amplified target was labeled and hybridized with
15 mg of the amplified target produced from an equivalent
amount of CPP amplified in parallel. After filtering the data
as described in the Materials and Methods section to include
only high-quality features, 1002 features that passed filter-
ing in at least 9 of 11 arrays and showed a standard deviation
of values z0.3 were used for unsupervised average-linkage
hierarchical clustering with Cluster and visualized with Tree-
View (Figure 3). The four cancerous epithelial samples clus-
tered on a separate branch from the benign and stromal
samples, with the stromal samples on a distinct terminal
branch from the benign samples. Although a complete ex-
amination of differentially expressed genes is outside the
scope of this study, a region of interest that demonstrates
the usefulness of LCM and WTA for profiling studies was
highlighted. Gene names denoted in red in the inset region
have been identified in at least one profiling study of grossly
dissected samples as being significantly downregulated
(P < .05) in prostate cancer compared to benign samples
(including normal adjacent tissue and BPH), according to
Oncomine 2.0 (www.oncomine.org), a compendium of micro-
array profiling studies [26]. In our study, rather than being
downregulated in cancerous epithelium, these transcripts
were highly expressed in stroma compared to both cancerous
and normal epithelia.
WTA Is Compatible with Partially Degraded RNA
As WTA does not depend on the presence of a poly-A tail
on the RNA transcript, we sought to determine whether WTA
is compatible with degraded RNA, including RNA isolated
from FFPE samples. To assess the compatibility of WTA with
artificially degraded RNA, we used the same total RNA from
LnCAP cells treated with the androgen analogue R1881
or control (LnCAP_R or LnCAP_C, respectively), as in our
initial validation experiments (Figure 2C). Total RNA from
LnCAP_R and LnCAP_C was base-hydrolyzed for 5 or
15 minutes, and 25 ng was used for WTA cDNA library
synthesis and two rounds of WTA PCR amplification, labeling
(LnCAP_R, Cy5; LnCAP_C, Cy3), and hybridization. Results
of hybridization from 25 ng of the intact samples subjected
to WTA cDNA library synthesis and two rounds of WTA PCR
amplification, and these two degraded samples were com-
pared to the top 29 differentially expressed features iden-
tified from intact unamplified samples (Figure 4A). The
numbers below each column again indicate the percentage
of the top 29 differentially expressed features identified in
the unamplified array that had Z scores z1 or z2 on each
WTA hybridization. After 5 minutes of degradation resulting
in the absence of 28S and 18S ribosomal bands, 90% and
66% of the most differentially expressed genes identified
on the unamplified hybridization still had Z scores >1 or >2,
respectively. With further degradation, WTA-amplified sam-
ples still showed similar expression patterns to unamplified
intact RNA; however, there was decreased correlation to
the unamplified sample.
We also directly tested the usefulness of WTA with FFPE
samples, which are known to yield degraded RNA, due to
cross-linking between nucleic acids and proteins. Total RNA
was isolated from two 10-mm sections from grossly dissected
tumor samples (FFPE_PCA1 and FFPE_PCA2) and one
grossly dissected sample containing only benign tissue
(FFPE_NOR1) that had been fixed in formalin and embedded
in paraffin. Denaturing formaldehyde agarose gel electro-
phoresis revealed degradation in each FFPE RNA sample
compared to intact RNA (Figure 4B), as expected. Twenty-five
nanograms of isolated RNA was used to produce labeled
target for hybridization after WTA cDNA library synthesis and
two rounds of WTA PCR amplification. These samples were
hybridized against an equivalent amount of CPP subjected
to WTA cDNA library synthesis and two rounds of WTA PCR
amplification in parallel. Seventy features showing the
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greatest differential expression between the average of the
two cancer samples and the normal sample were visualized
with TreeView (Figure 4C). Genes denoted in green or red
have been identified in profiling studies as being significantly
dysregulated (P < .05), in the same direction, in at least one
profiling study comparing grossly dissected cancer and benign
samples (downregulated or upregulated, respectively) accord-
ing to Oncomine 2.0. A subset of differentially expressed
genes was validated using QPCR on directly reverse-
transcribed cDNA or WTA-amplified cDNA from FFPE_PCA1
(Figure 4D). Taken together, these results demonstrate the
ability of WTA to faithfully amplify partially degraded RNA,
including materials obtained from FFPE tissues.
Discussion
In this report, we describe the evaluation and validation of
OmniPlex WTA, a novel, exponential RNA amplification
Figure 3. WTA amplification from RNA isolated from LCM prostate tissue reveals unique signatures. Approximately 5000 to 10,000 cells from different cases
containing cancerous epithelia (LCM_PCA1–4), benign epithelia (LCM_NOR1–5), stroma adjacent to cancerous glands (LCM_STROMA1), and stroma from a
nodule of benign prostatic hypertrophy (LCM_STROMA2) from frozen prostate specimens were captured by LCM. Isolated total RNA was used for WTA cDNA
library synthesis and two rounds of WTA PCR amplification in parallel with an equal amount of CPP and hybridized. For each experiment, the LCM sample was
labeled with Cy5 (red), and CPP was labeled with Cy3 (green). The 1002 features that passed filtering on at least 9 of 11 arrays and showed a standard deviation of
z0.3 were clustered using unsupervised average-linkage hierarchical clustering with Cluster and visualized with TreeView (see Figure 2 for the matrix color
scheme). Names denoted in red in the inset region represent genes identified as being significantly (P < .05) underexpressed in tumor samples compared to
benign prostate in at least one previous profiling study using grossly dissected tissues according to Oncomine 2.0 (www.oncomine.org)—a compendium of cancer
microarray profiling studies.
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Figure 4.WTA gives high-fidelity results with partially degraded RNA and RNA isolated from FFPE samples. (A) Total RNA from the prostate cancer cell line LnCAP
treated with R1881 (R) or control (C), as described in Figure 2C, was hydrolyzed, and RNA integrity was determined. Twenty-five nanograms of hydrolyzed RNA was
used for WTA cDNA library synthesis and two rounds of WTA PCR before hybridization, as described in Figure 2C. Results were visualized with TreeView along with
corresponding hybridizations from intact unamplified total RNA and 25 ng of intact RNA subjected to two rounds of WTA (see Figure 2 for the matrix color scheme).
The number below each column indicates the percentage of these top 29 differentially expressed features identified in the unamplified array that had Z scores z1 or
z2 on the indicated WTA hybridization. (B) Total RNA was isolated from two sections from FFPE specimens containing prostate cancer (FFPE_PCA1–2) or benign
prostate (FFPE_NOR1). RNA integrity was determined using denaturing formaldehyde agarose gel electrophoresis and compared to intact total RNA as indicated.
(C) Twenty-five nanograms of total RNA from each FFPE sample was used for WTA cDNA library synthesis and two rounds of WTA PCR in parallel with an equal
amount of CPP, and hybridized. For each experiment, the FFPE sample was labeled with Cy5 (red), and CPPwas labeled with Cy3 (green). The 70 genes showing the
greatest differential expression between the cancer and normal samples were visualized using TreeView.Genes denoted in red or green represent genes identified as
being significantly (P < .05) dysregulated in the same direction in bulk tumor samples compared to normal prostate tissues (upregulated or downregulated,
respectively) in at least one profiling study using Oncomine 2.0. (D) Validation of differentially expressed genes using QPCR. Directly reverse-transcribed cDNA
(UNAMP) or WTA cDNA, as indicated from FFPE_PCA1 and CPP, was assessed using QPCR. The amount of each target gene for FFPE_PCA1 and CPP was
normalized to the corresponding amount of GAPDH for the sample. Data are presented as the ratio of FFPE_PCA1 to CPP for each target gene on a log scale.
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technique. Using cDNA microarrays, we demonstrate that
WTA cDNA synthesis and multiple rounds of exponential
amplification are highly reproducible. The reproducibility of
additional rounds of WTA PCR amplification allows WTA to
be used to archive valuable samples and serve as a distrib-
utable molecular library for reamplification. We also show
that WTA can be used to reliably detect differential expres-
sion of low- and high-copy transcripts in profiling studies
using a combination of cDNA microarrays and real-time
PCR. Although detailed comparison studies to standard
IVT techniques are still needed, we demonstrate that WTA
provides an attractive alternative for many cancer biology
applications where RNA amplification is desired. Further-
more, we have recently reported the discovery of recurrent
gene fusions of TMPRSS2 and ETS family members in
prostate cancer, based in part on a large-scale profiling study
using samples subjected to WTA [27].
To demonstrate the applicability of WTA in this study, we
combined WTA with LCM to profile normal epithelia, cancer-
ous epithelia, and stroma from frozen prostate tissues. Com-
paring our results to previous profiling studies using grossly
dissected tissues, we identified a cluster of genes that had
been identified in profiling studies using grossly dissected
samples as being downregulated in prostate cancer com-
pared to benign tissue. However, our results show that
these transcripts are expressed at lower levels in both can-
cerous and normal epithelia, with much stronger expression
in the stromal compartment. Many of these features, in-
cluding smooth muscle actin (ACTA2, ACTC, ACTN1, and
ACTG2), smooth muscle myosin (MYL9 and MYH11), and
smooth muscle calponin (CNN1), represent transcripts
expressed predominantly in smooth muscle cells, which are
known to be a major component of prostate stroma [28]. A
recent study using in silico analysis also determined that the
majority of transcripts identified in profiling studies as being
‘‘downregulated’’ from normal prostate to prostate cancer
in fact represents stromal transcripts [29]. Taken together,
these results show thatWTA, in conjunction with LCM, can be
used for profiling studies where increased specificity over
grossly dissected tissue is desired. This specificity may be
crucial for studies profiling tumors such as prostate cancer,
where both benign and cancerous cells and multiple tissue
types may be present.
WTA does not require the presence of a poly-A tail, as
the cDNA synthesis step is not restricted to oligo-dT priming,
as is the case with most IVT-based and exponential am-
plification techniques. We confirmed that WTA amplifies
sequences distal to the 3V terminus by selecting QPCR
amplicons for TNFAIP3, AMACR, ZNF217, THBS1, WSB1,
HIF1A, andMYO6 located 1.7 to 2.5 kb from any known poly-
A sites, all of which were robustly amplified fromWTA cDNA.
Preliminary experiments using Affymetrix GeneChips also
demonstrated no 3V bias (data not shown). In this report, we
show that WTA can be used to reliably amplify artificially
degraded RNA, including samples with no detectable 18S
and 28S ribosomal bands. As a final demonstration of
applicability, we used WTA to profile cancerous and benign
FFPE prostate tissue samples and confirmed the fidelity of
WTA using QPCR. These results suggest that WTA may be
used to profile cohorts of FFPE tissue samples with long-
term clinical follow-up, which are often unavailable in frozen
tissue banks. Studies are underway to evaluate the effects of
the age of samples and the extent of RNA degradation in
FFPE samples on the reproducibility and fidelity of WTA.
Taken together, these experiments demonstrate that WTA
and expression profiling could be ideal for many diagnostic
and prognostic applications with limiting sample size, such
as needle biopsies, LCM, and FFPE. As the WTA method-
ology leads to the generation of a reamplifiable cDNA library,
it is ideally suited for the development of a molecular archive
that can serve as a distributable resource.
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